By Dan Bobear (@dbobear)
Now that AstraZeneca’s experimental blood thinner Brilinta has been given the green light by an advisory committee of the U.S. Food and Drug Administration, they need to prepare for the next hurdle they face: usurping category leader, Plavix, which is slated for generic availability sometime next year.
Most critical: changing physician prescribing behavior.
The [...]
